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Abstract To determine (1) the medium-term effect
of rosiglitazone and glipizide on intra-stent neointima
hyperplasia, (2) restenosis pattern as assessed by intra-
vascular ultrasound (IVUS) and quantitative coronary
angiography (QCA) in patients with T2DM and
coronary artery disease. A total of 462 patients with
T2DM were randomized to rosiglitazone or glipizide
for up to 18 months in the APPROACH trial, and had
evaluable baseline and follow-up IVUS examinations.
There was no significant difference in the size of plaque
behind stent between the rosiglitazone and glipizide
groups at 18 months among those treated with a bare
metal stent (-5.6 mm3 vs. 1.9 mm3; P = 0.61) or with
a drug-eluting stent (12.1 mm3 vs. 5.5 mm3; P = 0.09).
Similarly, there was no significant difference in
percentage intimal hyperplasia volume between the
rosiglitazone and glipizide groups at 18 months among
those treated with a bare metal stent (24.1% vs. 19.8%;
P = 0.38) or with a drug-eluting stent (9.8% vs. 8.3%;
P = 0.57). QCA data (intra-stent late loss, intra-stent
diameter stenosis or binary restenosis) were not
different between the rosiglitazone and glipizide
groups. This study suggests that both rosiglitazone
and glipizide have a similar effect on neointimal growth
at medium term follow-up, a finding that warrants
investigation in dedicated randomized trials.
Keywords Restenosis  Type 2 diabetes  IVUS 
Atherosclerosis
Introduction
The APPROACH (Assessment on the Prevention of
Progression by Rosiglitazone On Atherosclerosis in
diabetes patients with Cardiovascular History) study
Trial Registration: Clinicaltrials.gov NCT00116831.
http://clinicaltrials.gov/ct2/show/NCT00116831.
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was a double-blind randomized clinical trial compar-
ing the effects of rosiglitazone with glipizide on the
progression of coronary atherosclerosis [1, 2].
Patients with Type 2 diabetes mellitus (T2DM) are
at increased risk for restenosis after intracoronary
stent placement [3–6]. Moreover, prior studies have
suggested that thiazolidinediones, which improve
insulin sensitivity and have effects on vascular
smooth muscle cell proliferation and neointimal
hyperplasia, may reduce rates of in-stent restenosis
in patients irrespective of their diabetic status [7–15].
The objectives of this pre-specified APPROACH
sub-study were: (1) to determine the effect of rosig-
litazone and glipizide on intra-stent neointima hyper-
plasia in patients with T2DM and coronary artery
disease (CAD); (2) to determine the restenosis param-
eters measured by intravascular ultrasound (plaque
behind stent, intra-stent intima hyperplasia volume);
and (3) to report the quantitative coronary angiography
(QCA) intra-stent late loss, intra-stent diameter steno-
sis [DS], and binary angiographic restenosis.
Materials and methods
Study design and eligibility criteria
A detailed description of the APPROACH trial
has been previously published [1]. In brief, the
APPROACH study was a prospective multicenter,
double-blind, randomized, active-controlled trial
(Fig. 1) of 672 patients from 92 centers in 19
countries, who were aged 30–80 years with estab-
lished T2DM and who had clinically indicated
coronary angiography or percutaneous coronary
intervention (PCI) between February 2005 and Jan-
uary 2007. Patients were included if they had at least
one atherosclerotic plaque with [50% luminal nar-
rowing in a coronary artery, and if their diabetes was
treated with either lifestyle approaches alone (with an
HbA1C [ 7 and B10%), or with oral agents
comprising 1 oral agent at any dose, or 2 oral agents
where each was prescribed at B50% of its maximal
dose (with an HbA1C [ 6.5 and B8.5%). Exclusion
criteria were: ST-segment elevation myocardial
infarction in the prior 30 days; coronary artery bypass
graft surgery; severe valvular heart disease; left
ventricular ejection fraction \40%; any heart failure
(New York Heart Association class I–IV); uncon-
trolled hypertension (systolic blood pressure [170
mmHg or diastolic blood pressure [100 mmHg);
renal insufficiency (serum creatinine C1.5 mg/dl for
men or C1.4 mg/dl for women); and active liver
disease. Participant safety was monitored by an
Independent Data Monitoring. Data analysis was
performed according to a pre-specified plan that
was developed with the approval of the steering
committee.
In this pre-specified analysis, all patients who
underwent stent placement during APPROACH and
Fig. 1 Patient disposition. CVD cardiovascular disease, GLP glipizide, IVUS intravascular ultrasound, PCI percutaneous coronary
intervention, RSG rosiglitazone, T2DM type 2 diabetes mellitus
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had available serial IVUS or QCA measurements
were included.
Quantitative angiography analysis
The angiograms were stored in DICOM format and
analyzed offline by Core laboratory personnel (Car-
dialysis, Rotterdam, The Netherlands), using the
CASS II analysis system (Pie Medical BV, Maas-
tricht, The Netherlands). The following quantitative
coronary angiography (QCA) analysis parameters
were measured: computed-defined minimal luminal
diameter (MLD) and reference vessel diameter
(RVD) obtained by an interpolate method.
Quantitative coronary angiography endpoints
Late loss was defined as the difference in minimum
lumen diameter between baseline and follow-up.
Percent diameter stenosis was defined as the
minimum lumen diameter divided by the reference
vessel diameter at the site of the MLD 9 100.
Binary angiographic restenosis was defined as
follow-up stenosis [50%. This is reported as fre-
quency and percentage.
Management of glycemia and follow-up
Patients were randomized in a 1:1 ratio to receive
masked rosiglitazone (4 mg/day) or glipizide (5 mg/
day) in one pill. After 2 and 3 months, the dose of
masked study drug was increased if tolerated and if the
mean daily glucose level calculated from the patient’s
logbook of capillary tests in the 3 days prior to the visit
was C126 mg/dl (7.0 mmol/l). If more than 1 titration
was required, 2 pills per day were given. Open-label
metformin (maximal total daily dose 2,550 mg) and
then once-daily basal insulin, or both was added after
the first 3 months if needed to maintain a HbA1c B 7%
using a glycemic titration algorithm designed to
provide comparable glycemic control between treat-
ment groups. Non-study drugs were reduced before
study drugs in the event of hypoglycemia requiring
dose reductions. Unless informed consent was for-
mally withdrawn, all patients were followed until
18 months from randomization and clinical status
ascertained regardless of whether they continued to
take study medication.
Intravascular ultrasound examination and
image analysis
Following stent implantation IVUS was performed.
After intracoronary administration of nitroglycerin,
an ultrasound catheter (2.5F Atlantis SR Pro Imaging
40 MHz) connected to a Galaxy G2 digital imaging
console (Boston Scientific, Natick, MA) was
advanced into the target vessel. The imaging trans-
ducer was positioned just distal to an identifiable side
branch, and then motorized pullback of the transducer
was performed at 0.5 mm/s. If a participant required
cardiac catheterization for a clinical indication
between 9 and 18 months, follow-up IVUS exami-
nation could be performed at that time instead of at
study completion.
Intravascular ultrasound outcomes
Core laboratory personnel (Cardialysis, Rotterdam,
The Netherlands) who were blinded to treatment
assignment analyzed all IVUS images using validated
software (Curad, version 3.1, Wijk bij Duurstede, The
Netherlands), that facilitates detection of luminal and
external elastic membrane (EEM—also called vessel
contour) boundaries in reconstructed longitudinal
planes. In order to obtain a smooth appearance of
the vessel wall structures in the longitudinal views,
the IntelligateTM image-based gating method was
applied [16, 17].
Intravascular ultrasound endpoints
Plaque behind stent was derived by subtracting the
mean stent area from the vessel mean area.
Percentage volume of intimal hyperplasia (%vol
IH) was defined as IH volume divided by stent
volume.
Statistical methods
For baseline characteristics, continuous variables are
expressed as mean and standard deviation, or median
and interquartile range if non-normally distributed,
with categorical variables reported as percentage. For
continuous variables P values were based on Wilco-
xon test, while for categorical variables P values were
based on Fisher’s exact test. The P values for
treatment difference of continuous IVUS and QCA
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variables were based on analysis of covariance model
(ANCOVA) with terms for treatment, baseline mea-
surement, region, gender, cardiac procedure, and
prior OAD medication. Two sample test was used for
group comparisons at baseline and follow-up. For
binary angiographic restenosis, Fisher’s exact test
was used.
Results
Participants
In total 672 (68% men) of mean (SD) age 61 (9)
years, median diabetes duration of 4.8 years and
mean haemoglobin HbA1C of 7.2 (0.9) % were
randomized to either glipizide (N = 339) or rosiglit-
azone (N = 333) from 92 sites in 19 countries
(Fig. 1). At the end of the study, 462 randomized
patients had evaluable baseline and follow-up IVUS
examinations. 173 had evaluable angiographic data
and 113 had serial IVUS data from a vessel with PCI
at baseline.
Patients were followed for a median of 18.6
months (IQR 18.2–18.9) and a mean (SD) of 16 (6)
months; patients allocated to glipizide were adherent
at 90.7% of visits and those allocated to rosiglitazone
were adherent at 92.7% of visits.
In this analysis, 231 patients who underwent stent
placement during the study and had available serial
IVUS or QCA measurements were included. Patients
who underwent stent placement do not represent
randomized groups, however the distribution of these
patients was similar between the randomized groups
(glipizide N = 118, rosiglitazone N = 113).
Baseline characteristics were generally similar
between the groups. (Table 1). Patients in the rosig-
litazone group had slightly higher serum creatinine,
compared with glipizide (P = 0.01).
All the DES implanted were from 1st DES
generation. No difference in stent size were found
between groups (Table 2).
Effect on intravascular ultrasound endpoints
There was no significant difference in the size of plaque
behind stent between the rosiglitazone and glipizide
groups at 18 months among those treated with a bare
metal stent (-5.6 mm3 vs. 1.9 mm3; P = 0.61) or with
a drug-eluting stent (12.1 mm3 vs. 5.5 mm3; P = 0.09)
(Table 3). Similarly, there was no significant difference
in percentage intimal hyperplasia volume between the
rosiglitazone and glipizide groups at 18 months among
those treated with a bare metal stent (24.1% vs. 19.8%;
P = 0.38) or with a drug-eluting stent (9.8% vs. 8.3%;
P = 0.57) (Table 3).
Effect on QCA endpoints
Intra-stent late loss did not differ between the
rosiglitazone and glipizide groups among those with
a bare metal stent (0.76 mm vs. 0.71 mm; P = 0.51)
or a drug-eluting stent (0.37 vs. 0.25; P = 0.41)
(Table 3). There was no difference in intra-stent
diameter stenosis between the rosiglitazone and
glipizide groups among those with a bare metal stent
(32.3% vs. 30.4%; P = 0.50) or a drug-eluting stent
(22.1% vs. 17.9%; P = 0.28) (Table 3). The per-
centage of patients with binary angiographic reste-
nosis did not differ between the rosiglitazone and
glipizide groups among those with a bare metal stent
(22.9% vs. 10.8%; P = 0.21) or a drug-eluting stent
(4.6% vs. 1.8%; P = 0.58) (Table 3).
Safety
As noted previously, the patients who underwent
stent placement do not represent randomized groups,
however, there were no significant differences in
cardiovascular events between the rosiglitazone and
glipizide groups, which occurred infrequently during
the trial (Table 4).
In the rosiglitazone group, 5 cardiovascular events
occurred within 5 days of the baseline cardiac
catheterization and were classified as procedure-
related. These events included one revascularization,
two nonfatal myocardial infarctions, one nonfatal
stroke and one cardiovascular death.
Discussion
This study demonstrates no additional advantage of
using rosiglitazone over glipizide in Type 2 diabetic
patients for the reduction of in-stent restenosis;
however it did demonstrate that both drugs have
comparable effect on neointimial growth up to
18-months after coronary stent implantation.
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Table 1 Baseline characteristics of intervened patients
Glipizide (N = 118) Rosiglitazone (N = 113) P value
Demographic characteristics
Age, mean (SD), years 60.4 (9.1) 62.4 (8.1) 0.14
Male, n (%) 84 (71.2%) 92 (81.4%) 0.09
Weight, mean (SD), kg 81.9 (17.5) 80.2 (17.3) 0.56
BMI, mean (SD), kg/m2 29.2 (4.9) 28.7 (5.3) 0.30
Duration of diabetes, median [IQR], years 4.5 [1.5–9.5] 4.5 [1.9–8.7] 0.77
Hypertension, n (%) 91 (77.1%) 88 (77.9%) 1.00
Dyslipidemia, n (%) 72 (61.0%) 74 (65.5%) 0.50
Prior myocardial infarction, n (%) 38 (32.2%) 28 (24.8%) 0.24
Presenting condition, n (%)
Acute coronary syndrome 60 (50.9%) 55 (48.7%) 0.79
Elective procedure 58 (49.2%) 58 (51.3%)
Baseline procedure, n (%)
Coronary angiography 6 (5.1%) 6 (5.3%) 1.00
Percutaneous coronary intervention 112 (94.9%) 107 (94.7%)
Current smoker, n (%) 20 (17.0%) 24 (21.2%) 0.50
ACC/AHA lesion type, n (%)
A 14 (11.7) 14 (12.1) 0.53
B1 49 (41.5) 48 (42.6)
B2 35 (29.7) 32 (28.3)
C 20 (17.1) 19 (17.0)
Prior medication use
Aspirin 106 (89.8%) 102 (90.3%) 1.00
Other anti-platelet 109 (92.4%) 108 (95.6%) 0.41
Beta-blocker 88 (74.6%) 86 (76.1%) 0.88
ACE inhibitor or ARB 80 (67.8%) 71 (62.8%) 0.49
Nitrates 57 (48.3%) 56 (49.6%) 0.90
Statin 97 (82.2%) 94 (83.2%) 0.86
Fibrate or other lipid-lowering agent 7 (5.93%) 10 (8.9%) 0.46
Vital signs and laboratory values
Blood pressure, mean (SD), mmHg
Systolic 129.9 (15.5) 126.6 (15.5) 0.17
Diastolic 74.5 (9.5) 73.2 (10.3) 0.41
HbA1c, mean (SD), % 7.1 (0.8) 7.0 (0.7) 0.14
Serum creatinine, mean (SD), lmol/L 85.2 (19.5) 93.7 (26.0) 0.01
BNP, median [IQR], pg/mL 30 [14–68] 25 [12–58] 0.50
Fasting insulin, median [IQR], lU/mL 12.1 [8.6–19.0] 13.0 [8.6–18.1] 0.96
LDL cholesterol, mean (SD), mg/dL 87.6 (38.0) 85.5 (36.6) 0.66
HDL cholesterol, mean (SD), mg/dL 41.2 (10.5) 40.9 (9.9) 0.79
Triglycerides, median [IQR], mg/dL 154.0 [113.7–200.9] 161.1 [123.9–192.0] 0.61
hsCRP, median [IQR], mg/L 5.1 [2.4–11.7] 6.1 [3.7–13.3] 0.19
MMP-9, median [IQR], lg/L 102.1 [48.1–202.4] 73.2 [38.4–159.9] 0.38
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On face value these results appear to contrast with
the majority of the previously conducted studies,
which have all reported significant reductions in the
rates of in-stent restenosis in patients treated with
thiazolidinediones compared to controls [7–15].
However it must be appreciated that these previous
studies have inherent limitations which include: small
sample sizes; a single-center location; the lack of
independent core lab analysis; short follow-up; and
PCI performed using only BMS. The recent POPPS
study by Takagi et al. [7] is an exception in view of its
multi-center recruitment, and use of an independent
core lab; however patients were still only treated with
BMS, and follow-up was reported at only 6-months.
On the contrary, the current study has distinct
advantages in addition to being the largest single
assessment to date of in-stent restenosis in patients
treated with thiazolidinediones. These additional
advantages include medium term follow-up, the use
of both bare and drug eluting stents, and IVUS/QCA
analysis performed by an independent core lab.
In the recent POPPS study, the neointimal growth
index (neointimal volume/stent volume 9100) at
6-months amongst patients who were received a
BMS, and treatment with pioglitazone and controls
was 31 and 40% respectively [7]; similarly in the
current study the respective values of this index at
18-months for rosiglitazone and glipizide were 24
and 19%, respectively. Whilst the results for rosig-
litazone are perhaps expected, the change noted with
glipizide although welcome is unexpected, and
obviously warrants further investigation.
The significance of the different follow-up periods,
which were between 6–9 months in the earlier studies
and 18-months in the current study, cannot be
overstated. Previous IVUS studies have clearly
demonstrated that neointimal growth continues to
progress up to 18-months after implantation of a
BMS, before regressing [18]. This key observation
not only highlights the importance of documenting
the point in time when IVUS measurements are
made, and keeping this in mind when interpreting the
IVUS findings; but also indicates the arduous nature
of trying to compare results from the current study to
previous studies. Nevertheless, in the present study
the comparatively lower rates of neointimal growth
seen at 18-months, reiterates a comparable effect of
both rosiglitazone and glipizide.
In-stent restenosis remains one of the undesired
consequences of PCI, and although the introduction
of drug eluting stents in 2002 improved rates of
restenosis, they have been unable to eliminate it [19].
There is a widely held misconception that restenosis
is a benign phenomenon; however it is associated
with both morbidity and mortality. In simplistic
terms, restenosis increases the requirement for a
repeat PCI procedure, which in itself is not risk free.
For example a mortality rate of 2.5% was observed in
the Ontario registry in those patients having target
vessel revascularisation within a month of their initial
PCI procedure [20]. In addition rates of MI related to
restenosis have been reported to be between 2 and
19% [21, 22].
In view of this it is no surprise that there is a great
desire to identify adjunctive agents which may help
reduce in-stent restenosis. This problem is particu-
larly pertinent in diabetic patients owing to the
identification of diabetes as an independent predictor
of in-stent restenosis [3, 4]. The mechanisms under-
lying this increased risk are poorly understood,
however it is considered amongst others to be the
result of a combination of the greater degree of the
vascular inflammation, and endothelial dysfunction
seen in diabetics [23, 24]. The risk of in-stent
restenosis is further compounded in T2DM patients
because insulin resistance can aggravate restenosis,
through the direct growth-factor like effect of insulin
on vascular smooth muscle and neointimal cells [25].
Poor glycaemic control is also implicated in
promoting restenosis [26], however previous studies
Table 2 Stent size distribution in the groups
Bare metal stent Drug-eluting stent
Glipizide N = 21 Rosiglitazone N = 21 P value Glipizide N = 40 Rosiglitazone N = 31 P value
Diameter 2.79 ± 0.60 3.05 ± 0.83 0.126 2.58 ± 0.71 2.68 ± 0.54 0.592
Length 18.00 ± 7.20 17.25 ± 5.10 0.833 21.45 ± 7.81 19.58 ± 7.02 0.257
In this post-hoc analysis, neither rosiglitazone nor glipizide are randomized groups
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Table 3 Results of quantitative coronary angiographic analysis
IVUS measurement Bare metal stent P value Drug-eluting stent P value
Glipizide
N = 21
Rosiglitazone
N = 21
Glipizide
N = 40
Rosiglitazone
N = 31
Mean (SD), mm3
Vessel volume
Baseline 302.3 (161.4) 245.1 (104.3) 0.18 278.6 (132.6) 302.4 (110.1) 0.42
Follow-up 302.3 (160.5) 241.0 (110.0) 0.16 288.6 (141.9) 317.3 (102.6) 0.35
Change from baseline 0.0 (29.3) -4.1 (39.8) 10.0 (23.0) 14.9 (34.1)
Model-adjusted change
(SE)
8.7 (16.6),
P = 0.60
9.8 (16.3), P = 0.55 6.7 (13.9) P = 0.62 14.0 (14.3),
P = 0.33
Treatment difference
(95% CI)
1.1 (-24.9,27.1) 0.93 7.3 (-7.4, 22.0) 0.32
Stent volume
Baseline 147.4 (81.1) 125.8 (53.1) 0.31 140.5 (64.4) 152.9 (61.0) 0.42
Follow-up 145.5 (78.7) 127.3 (60.0) 0.41 145.0 (65.8) 155.7 (53.4) 0.47
Change from baseline -1.9 (15.4) 1.5 (16.4) 4.5 (10.8) 2.8 (17.3)
Model-adjusted change
(SE)
-1.2 (7.9),
P = 0.88
3.5 (7.6), P = 0.65 0.3 (6.7), P = 0.96 -0.4 (6.9),
P = 0.95
Treatment difference
(95% CI)
4.7 (-7.3, 16.6) 0.43 -0.7 (-7.8, 6.4) 0.84
Plaque behind stent
Baseline 154.9 (83.3) 119.3 (57.5) 0.11 138.1 (77.9) 149.6 (59.7) 0.50
Follow-up 156.8 (85.2) 113.7 (54.4) 0.06 143.6 (83.6) 161.7 (58.7) 0.29
Change from baseline 1.9 (19.1) -5.6 (26.0) 5.5 (16.9) 12.1 (22.4)
Model-adjusted change
(SE)
10.3 (10.5),
P = 0.33
6.0 (10.6), P = 0.58 5.7 (9.4), P = 0.54 14.3 (9.7), P = 0.15
Treatment difference
(95% CI)
-4.3 (-21.2, 12.6) 0.61 8.6 (-1.4, 18.5) 0.09
%volume of IH*
Baseline -0.1 (0.2) -0.01 (0.1) 0.25 -0.3 (1.0) -0.3 (0.80) 0.75
Follow-up 19.7 (11.1) 24.1 (17.1) 0.33 8.0 (8.7) 9.6 (11.3) 0.51
Change from baseline 19.8 (11.1) 24.1 (17.1) 8.3 (8.7) 9.8 (11.3)
Model-adjusted change
(SE)
19.1 (7.2),
P = 0.01
23.9 (7.17),
P = 0.002
19.7 (4.3),
P \ 0.0001
21.0 (4.4),
P \ 0.0001
Treatment difference
(95% CI)
4.9 (-6.2, 15.9) 0.38 1.3 (-3.2, 5.8) 0.57
QCA measurement Bare metal stent P value Drug-eluting stent P value
Glipizide
N = 37
Rosiglitazone
N = 35
Glipizide
N = 57
Rosiglitazone
N = 44
In-stent late loss (mm)
Mean 0.71 0.76 0.25 0.37
SD 0.380 0.572 0.304 0.586
Model –adjusted Mean at month 18 (SE) 0.85 (0.151) 0.93 (0.162) 0.51 0.75 (0.177) 0.82 (0.183) 0.41
In-stent DS (%)
Mean 30.4 32.3 17.9 22.1
SD 15 18 12 20
Model-adjusted Mean at month 18 (SE) 32.98 (5.32) 35.92 (5.678) 0.50 32.57 (6.346) 35.82 (6.53) 0.28
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which have reported the benefit of thiazolidinediones
in reducing restenosis have indicated that this benefit
occurs independently of the drug’s effect on glycae-
mic control [7]. There are many potential mecha-
nisms by which thiazolidinediones may reduce
in-stent restenosis including: (a) the inhibition of
smooth muscle cell migration and proliferation [27,
28]; (b) the increased apoptosis in vascular smooth
muscle cells [29]; (c) a beneficial effect on local
inflammation [30, 31]; (d) an anti-thrombotic effect
[32]; and (e) a beneficial effect on fasting insulin
levels, thereby preventing insulin driven atheroscle-
rosis [25, 33].
In the end, it is important to highlight recent
concerns associated with rosiglitazone use. Follow-
ing drug launch, a metanalysis published in 2007
showed, indeed, an increased risk of myocardial
infarction and cardiovascular death associated with
rosiglitazone [34]. The recent RECORD trial also
demonstrated an increased risk of heart failure events
in people treated with rosiglitazone [35]. Eventually,
the FDA mandated a study comparing rosiglitazone
and pioglitazone with placebo, known as TIDE and
then stopped the inclusion of the patients. Rosiglit-
azone has subsequently been removed from the
EU market however it remains on available on the
US market albeit with severe restrictions.
Limitations
IVUS analyses were available in half of the patients
included in the present study and could not be
representative of overall population. Stent design was
not pre-specified for the different groups.
Conclusions
This study indicates that both rosiglitazone and
glipizide have a similar effect on neointimal growth
at medium term follow-up, a finding that warrants
investigation in dedicated randomized trials.
Table 4 Adverse cardiovascular events occurring either on-
therapy or post-therapy
Patients with
an event, n (%)
Glipizide
(N = 118)
(%)
Rosiglitazone
(N = 113)
(%)
All-cause death 3 (2.5) 5 (4.4)
Cardiovascular death 1 (0.8) 2 (1.8)
Stroke 0 (0.0) 2 (1.8)
Myocardial infarction 2 (1.7) 5 (4.4)
Nonfatal MI 1 (0.8) 4 (3.5)
Fatal MI 1 (0.8) 1 (0.9)
Cardiovascular death, nonfatal
stroke, or nonfatal MI
2 (1.7) 7 (6.2)
Coronary revascularisation 14 (11.9) 15 (13.3)
In this post-hoc analysis, neither rosiglitazone nor glipizide are
randomized groups
Table 3 continued
QCA measurement Bare metal stent P value Drug-eluting stent P value
Glipizide
N = 37
Rosiglitazone
N = 35
Glipizide
N = 57
Rosiglitazone
N = 44
RVD (mm)
Mean 2.62 2.58 2.62 2.78
SD 0.51 0.47 0.42 0.44
Model-adjusted Mean at month 18 (SE) 2.51 (0.100) 2.53 (0.108) 0.76 2.61 (0.121) 2.67 (0.125) 0.32
MLD (mm)
Mean 1.84 1.75 2.15 2.27
SD 0.59 0.56 0.46 0.45
Model-adjusted Mean at month 18 (SE) 1.68 (0.151) 1.60 (0.162) 0.50 1.78 (0.141) 1.79 (0.146) 0.86
Binary angiographic restenosis, n(%) 4 (10.81) 8 (22.86) 0.21 1 (1.75) 2 (4.55) 0.58
In this post-hoc analysis, neither rosiglitazone nor glipizide are randomized groups; *%vol IH percentage volume of intimal
hyperplasia
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